Deciphera Pharmaceuticals, Inc. (DCPH) Given Average Recommendation of “Strong Buy” by Analysts

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokers have set a 1-year consensus target price of $34.33 for the company, according to Zacks. Zacks has also assigned Deciphera Pharmaceuticals an industry rank of 109 out of 265 based on the ratings given to its competitors.

A number of equities analysts recently commented on DCPH shares. Instinet started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $57.00 target price for the company. Nomura started coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set a “buy” rating and a $57.00 target price for the company. JMP Securities initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They set an “outperform” rating and a $38.00 target price for the company. J P Morgan Chase & Co initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Piper Jaffray Companies initiated coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price objective for the company.

Deciphera Pharmaceuticals (NASDAQ DCPH) traded up 0.52% during mid-day trading on Tuesday, hitting $19.19. 94,859 shares of the stock traded hands. The company has a 50-day moving average of $20.87 and a 200 day moving average of $20.87. Deciphera Pharmaceuticals has a 1-year low of $16.11 and a 1-year high of $24.50. The firm’s market capitalization is $612.64 million.

COPYRIGHT VIOLATION WARNING: “Deciphera Pharmaceuticals, Inc. (DCPH) Given Average Recommendation of “Strong Buy” by Analysts” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/10/31/deciphera-pharmaceuticals-inc-dcph-given-average-recommendation-of-strong-buy-by-analysts.html.

In other news, major shareholder New Leaf Venture Management Ii acquired 375,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was acquired at an average price of $17.00 per share, for a total transaction of $6,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DCPH. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Deciphera Pharmaceuticals in the third quarter worth $2,172,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Deciphera Pharmaceuticals in the third quarter worth $5,548,000. Finally, Emerald Advisers Inc. PA purchased a new stake in shares of Deciphera Pharmaceuticals in the third quarter worth $6,661,000.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

What are top analysts saying about Deciphera Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Deciphera Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit